C WorldWide Group Holding A S raised its holdings in Coherus Biosciences Inc (NASDAQ:CHRS) by 19.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 808,464 shares of the biotechnology company’s stock after purchasing an additional 130,000 shares during the quarter. C WorldWide Group Holding A S owned 1.16% of Coherus Biosciences worth $16,379,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the business. Jacobs Levy Equity Management Inc. raised its holdings in shares of Coherus Biosciences by 45.5% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 137,591 shares of the biotechnology company’s stock valued at $3,041,000 after buying an additional 43,005 shares during the period. Cadence Capital Management LLC purchased a new stake in shares of Coherus Biosciences in the 3rd quarter valued at $2,634,000. Calamos Advisors LLC purchased a new stake in shares of Coherus Biosciences in the 2nd quarter valued at $972,000. DekaBank Deutsche Girozentrale raised its holdings in shares of Coherus Biosciences by 300.9% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 85,400 shares of the biotechnology company’s stock valued at $1,835,000 after buying an additional 64,100 shares during the period. Finally, Atika Capital Management LLC raised its holdings in shares of Coherus Biosciences by 11.7% in the 2nd quarter. Atika Capital Management LLC now owns 210,000 shares of the biotechnology company’s stock valued at $4,641,000 after buying an additional 22,000 shares during the period. Institutional investors own 96.37% of the company’s stock.
Several research firms recently issued reports on CHRS. Barclays set a $31.00 price objective on Coherus Biosciences and gave the company a “buy” rating in a report on Monday, August 12th. Zacks Investment Research raised Coherus Biosciences from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Thursday. Mizuho set a $43.00 target price on Coherus Biosciences and gave the stock a “buy” rating in a research note on Sunday, September 29th. BidaskClub cut Coherus Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, October 16th. Finally, Citigroup boosted their target price on Coherus Biosciences from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday. Two research analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $30.38.
In other news, COO Vincent R. Anicetti sold 2,500 shares of the company’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $19.00, for a total transaction of $47,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jean-Frederic Viret sold 6,318 shares of the company’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $21.71, for a total value of $137,163.78. Following the transaction, the chief financial officer now directly owns 14,831 shares of the company’s stock, valued at $321,981.01. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,264 shares of company stock valued at $504,967. Insiders own 18.20% of the company’s stock.
CHRS traded up $0.06 on Friday, hitting $19.06. 1,353,212 shares of the company were exchanged, compared to its average volume of 992,812. Coherus Biosciences Inc has a twelve month low of $8.32 and a twelve month high of $23.91. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -5.93 and a beta of 2.90. The firm has a 50-day moving average price of $19.23 and a two-hundred day moving average price of $19.16.
Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.27. The business had revenue of $111.68 million for the quarter, compared to analyst estimates of $93.58 million. Research analysts forecast that Coherus Biosciences Inc will post 0.89 earnings per share for the current fiscal year.
Coherus Biosciences Profile
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Further Reading: Bond
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.